LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,991
تعداد مشاهده مقاله26,160,994
تعداد دریافت فایل اصل مقاله7,234,065
Jafari, Seyed Hamed, Jahanmir, Armaghan, Bahramvand, Yaser, Tahmasebi, Sedigheh, Dallaki, Manoochehr, Nasrollahi, Elham. (1400). Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran. سامانه مدیریت نشریات علمی, 47(1), 40-47. doi: 10.30476/ijms.2021.88366.1906
Seyed Hamed Jafari; Armaghan Jahanmir; Yaser Bahramvand; Sedigheh Tahmasebi; Manoochehr Dallaki; Elham Nasrollahi. "Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran". سامانه مدیریت نشریات علمی, 47, 1, 1400, 40-47. doi: 10.30476/ijms.2021.88366.1906
Jafari, Seyed Hamed, Jahanmir, Armaghan, Bahramvand, Yaser, Tahmasebi, Sedigheh, Dallaki, Manoochehr, Nasrollahi, Elham. (1400). 'Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran', سامانه مدیریت نشریات علمی, 47(1), pp. 40-47. doi: 10.30476/ijms.2021.88366.1906
Jafari, Seyed Hamed, Jahanmir, Armaghan, Bahramvand, Yaser, Tahmasebi, Sedigheh, Dallaki, Manoochehr, Nasrollahi, Elham. Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran. سامانه مدیریت نشریات علمی, 1400; 47(1): 40-47. doi: 10.30476/ijms.2021.88366.1906

Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran

Iranian Journal of Medical Sciences
مقاله 6، دوره 47، شماره 1، فروردین 2022، صفحه 40-47    اصل مقاله (559.51 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2021.88366.1906
نویسندگان
Seyed Hamed Jafari1، 2؛ Armaghan Jahanmir2؛ Yaser Bahramvand2؛ Sedigheh Tahmasebi3؛ Manoochehr Dallaki2؛ Elham Nasrollahi* 2
1Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Radiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Metastasis is an important factor in the survival estimate of patients with breast cancer. The present study aimed to examine the frequency of epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression in relation to the metastatic site, pattern, and tumor size in patients with metastatic breast cancer (MBC).
Methods: In this retrospective study, the medical records of patients diagnosed with MBC at Motahari Clinic (Shiraz, Iran) during 2017-2019 were examined. Metastasis was confirmed using computed tomography, and a total of 276 patients were included in the study. Based on the expression of receptors, the patients were categorized into luminal A, luminal B, HER2, and TNBC groups. The frequency and percentage of receptors in relation to the metastatic site, size, and pattern were compared using the Chi square test. p Results: The frequency of receptor positivity in the 276 selected medical records were of the subtype HER2-enriched (n=48), luminal A (n=43), luminal B (n=146), and TNBC (n=39). The most common metastatic sites were the bones (47.1%), lungs (34.4%), liver (27.9%), brain (20.3%), and other organs (12.7%). The first site of metastasis occurred in the bones (36.6%), lungs (17.4%), liver (15.6%), brain (10.5%), and other organs (7.6%). The frequency of receptor expression was different in relation to the first metastatic site (P=0.024). There was a statistically significant difference between the frequency of receptor expression in patients with bone (P=0.036), brain (P=0.031), and lung (P=0.020) metastases. The frequency of receptor expression was also significantly different in relation to the size of liver metastasis (P=0.009). Luminal A and B subtypes showed higher rates of bone metastasis as the first metastatic site.
Conclusion: The difference in the frequency of receptor expression in relation to the metastatic site and tumor size can be used as predictive and prognostic factors in patients with breast cancer.
کلیدواژه‌ها
Breast neoplasms؛ Neoplasm metastasis؛ Receptors؛ Progesterone
سایر فایل های مرتبط با مقاله
مراجع
  1. Rojas K, Stuckey A. Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol. 2016;59:651-72. doi: 10.1097/GRF.0000000000000239. PubMed PMID: 27681694.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. doi: 10.3322/caac.21551. PubMed PMID: 30620402.
  3. Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol. 2015;39:519-27. doi: 10.1016/j.canep.2015.04.016. PubMed PMID: 26070507.
  4. Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011;22:93-7. doi: 10.1093/annonc/mdq303. PubMed PMID: 20534622.
  5. Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Pourhoseingholi A, Barzegar F, et al. Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev. 2012;13:367-70. doi: 10.7314/apjcp.2012.13.1.367. PubMed PMID: 22502702.
  6. Jin X, Mu P. Targeting Breast Cancer Metastasis. Breast Cancer (Auckl). 2015;9:23-34. doi: 10.4137/BCBCR.S25460. PubMed PMID: 26380552; PubMed Central PMCID: PMCPMC4559199.
  7. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19:1091. doi: 10.1186/s12885-019-6311-z. PubMed PMID: 31718602; PubMed Central PMCID: PMCPMC6852913.
  8. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017;13:1387-97. doi: 10.7150/ijbs.21635. PubMed PMID: 29209143; PubMed Central PMCID: PMCPMC5715522.
  9. Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27:95-120. doi: 10.1016/j.soc.2017.08.005. PubMed PMID: 29132568; PubMed Central PMCID: PMCPMC5715810.
  10. Siersbaek R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor alpha function in breast cancer. Genes Dev. 2018;32:1141-54. doi: 10.1101/gad.316646.118. PubMed PMID: 30181360; PubMed Central PMCID: PMCPMC6120708.
  11. Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, et al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015;22:S95-S113. doi: 10.3747/co.22.2326. PubMed PMID: 25848344; PubMed Central PMCID: PMCPMC4381796.
  12. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412-24. doi: 10.5306/wjco.v5.i3.412. PubMed PMID: 25114856; PubMed Central PMCID: PMCPMC4127612.
  13. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, et al. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus. 2016;8:e924. doi: 10.7759/cureus.924. PubMed PMID: 28090417; PubMed Central PMCID: PMCPMC5222631.
  14. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016;16:734. doi: 10.1186/s12885-016-2766-3. PubMed PMID: 27634735; PubMed Central PMCID: PMCPMC5024419.
  15. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell. 2017;168:670-91. doi: 10.1016/j.cell.2016.11.037. PubMed PMID: 28187288; PubMed Central PMCID: PMCPMC5308465.
  16. Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018;10:5329-38. doi: 10.2147/CMAR.S176763. PubMed PMID: 30464629; PubMed Central PMCID: PMCPMC6225920.
  17. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8:27990-6. doi: 10.18632/oncotarget.15856. PubMed PMID: 28427196; PubMed Central PMCID: PMCPMC5438624.
  18. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411-25. doi: 10.1038/nrc3055. PubMed PMID: 21593787; PubMed Central PMCID: PMCPMC3666847.
  19. Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, et al. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019;19:857. doi: 10.1186/s12885-019-6073-7. PubMed PMID: 31464611; PubMed Central PMCID: PMCPMC6716879.
  20. Obenauf AC, Massague J. Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 2015;1:76-91. doi: 10.1016/j.trecan.2015.07.009. PubMed PMID: 28741564; PubMed Central PMCID: PMCPMC4673677.
  21. Kim JY, Lee YJ, Yoo TY, Kim JB, Hyun JH, Park IS, et al. Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics. Journal of Breast Disease. 2019;7:30-7. doi: 10.14449/jbd.2019.7.1.30.
  22. Pareek A, Singh OP, Yogi V, Ghori HU, Tiwari V, Redhu P. Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer. J Cancer Res Ther. 2019;15:971-5. doi: 10.4103/jcrt.JCRT_235_18. PubMed PMID: 31603096.
  23. Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, et al. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol. 2018;137:295-302. doi: 10.1007/s11060-017-2717-0. PubMed PMID: 29260362; PubMed Central PMCID: PMCPMC5851692.
  24. Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod Pathol. 2019;32:1244-56. doi: 10.1038/s41379-019-0270-4. PubMed PMID: 30976105; PubMed Central PMCID: PMCPMC6731159.
  25. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7. doi: 10.1200/JCO.2009.25.9820. PubMed PMID: 20498394.
  26. Gao JJ, Swain SM. Luminal A Breast Cancer and Molecular Assays: A Review. Oncologist. 2018;23:556-65. doi: 10.1634/theoncologist.2017-0535. PubMed PMID: 29472313; PubMed Central PMCID: PMCPMC5947456.
  27. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34:927-35. doi: 10.1200/JCO.2015.62.3504. PubMed PMID: 26786933; PubMed Central PMCID: PMCPMC4933127.
  28. Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016;156:249-59. doi: 10.1007/s10549-016-3741-z. PubMed PMID: 26965286; PubMed Central PMCID: PMCPMC4819548.
  29. Jin J, Gao Y, Zhang J, Wang L, Wang B, Cao J, et al. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. BMC Cancer. 2018;18:446. doi: 10.1186/s12885-018-4371-0. PubMed PMID: 29673325; PubMed Central PMCID: PMCPMC5909254.
  30. Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018;2:4. doi: 10.1038/s41698-018-0047-0. PubMed PMID: 29872722; PubMed Central PMCID: PMCPMC5871901.
  31. Niwinska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys. 2010;77:1134-9. doi: 10.1016/j.ijrobp.2009.06.030. PubMed PMID: 19932944.
  32. Yap YS, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107:1075-82. doi: 10.1038/bjc.2012.346. PubMed PMID: 22918394; PubMed Central PMCID: PMCPMC3461152.
  33. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674-90. doi: 10.1038/nrclinonc.2016.66. PubMed PMID: 27184417; PubMed Central PMCID: PMCPMC5461122.
  34. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010;12:S3. doi: 10.1186/bcr2574. PubMed PMID: 21050424; PubMed Central PMCID: PMCPMC2972557.
  35. Avraham HK, Jiang S, Fu Y, Nakshatri H, Ovadia H, Avraham S. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. J Pathol. 2014;232:369-81. doi: 10.1002/path.4304. PubMed PMID: 24421076.
آمار
تعداد مشاهده مقاله: 4,276
تعداد دریافت فایل اصل مقاله: 2,025


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب